Your browser doesn't support javascript.
loading
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial.
Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E; Becker, Richard C; Bertilsson, Maria; Budaj, Andrzej; Cornel, Jan H; Himmelmann, Anders; James, Stefan K; Siegbahn, Agneta; Storey, Robert F; Kontny, Frederic; Aukrust, Pål; Wallentin, Lars.
Afiliación
  • Ueland T; Research Institute of Internal Medicine, The National Hospital, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, University of Oslo, Norway; K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), University of Tromsø, Tromsø, Norway. Electronic address: thor.ueland
  • Åkerblom A; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Ghukasyan T; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Michelsen AE; Research Institute of Internal Medicine, The National Hospital, University of Oslo, Oslo, Norway.
  • Becker RC; Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Bertilsson M; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Budaj A; Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.
  • Cornel JH; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands.
  • Himmelmann A; AstraZeneca Research and Development, Gothenburg, Sweden.
  • James SK; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Siegbahn A; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden; Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
  • Storey RF; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
  • Kontny F; Stavanger University Hospital, Department of Cardiology, Stavanger, Norway; Drammen Heart Center, Drammen, Norway.
  • Aukrust P; Research Institute of Internal Medicine, The National Hospital, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, University of Oslo, Norway; K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), University of Tromsø, Tromsø, Norway; Section of Clinical Immunology
  • Wallentin L; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Atherosclerosis ; 293: 35-41, 2020 01.
Article en En | MEDLINE | ID: mdl-31835039
BACKGROUND AND AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is upregulated during inflammation and involved in transmigration of leukocytes and T-cell activation. We hypothesized that ALCAM might be associated with recurrent events in patients with acute coronary syndromes (ACS). METHODS: ALCAM was measured in serum obtained on admission, at discharge, 1 month and 6 months in a subgroup of 5165 patients admitted with ACS and included in the PLATelet inhibition and patient Outcomes (PLATO) trial (NCT00391872). The association between ALCAM and the composite endpoint and its components, including cardiovascular (CV) death, non-procedural spontaneous myocardial infarction (MI) or stroke during 1-year follow-up, was assessed by Cox proportional hazards models with incremental addition of clinical risk factors and biomarkers (including high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15). RESULTS: The median (Q1-Q3) concentration of ALCAM at admission was 97 (80-116) ng/mL. A 50% higher level of ALCAM on admission was associated with a hazard ratio (HR) of 1.16 (95% confidence interval [1.00-1.34] p = 0.043) for the composite endpoint in fully adjusted analysis, mainly driven by the association with CV death (HR 1.45 [1.16-1.82] p = 0.0012). CONCLUSIONS: In patients with ACS, admission level of ALCAM was independently associated with adverse outcome including CV death even after adjustment for established inflammatory and cardiac biomarkers.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD / Moléculas de Adhesión Celular Neuronal / Síndrome Coronario Agudo / Proteínas Fetales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Atherosclerosis Año: 2020 Tipo del documento: Article Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD / Moléculas de Adhesión Celular Neuronal / Síndrome Coronario Agudo / Proteínas Fetales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Atherosclerosis Año: 2020 Tipo del documento: Article Pais de publicación: Irlanda